Accession Number: | 0001209191-20-009834 |
Date: | 2020-02-13 |
Issuer: | ARENA PHARMACEUTICALS INC (ARNA) |
Original Submission Date: |
LIND KEVIN ROBERT
C/O ARENA PHARMACEUTICALS, INC.
6154 NANCY RIDGE DRIVE
SAN DIEGO, CA 92121
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2020-02-13 | M | 2,500 | a | $19.40 | 5,957 | direct | ||
COMMON STOCK | 2020-02-13 | M | 2,000 | a | $35.60 | 7,957 | direct | ||
COMMON STOCK | 2020-02-13 | S | 4,500 | d | $55.00 | 3,457 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EMPLOYEE STOCK OPTION (RIGHT TO BUY) | 19.4 | 2020-02-13 | deemed execution date | M | 2,500 (d) | 2023-06-15 | common stock 2,500 | $19.40 | 77,500 | direct | ||
EMPLOYEE STOCK OPTION (RIGHT TO BUY) | 35.6 | 2020-02-13 | deemed execution date | M | 2,000 (d) | 2025-01-19 | common stock 2,000 | $35.60 | 128,000 | direct |
ID | footnote |
---|---|
f1 | the transactions reported in this form 4 were effected pursuant to a rule 10b5-1 trading plan established by the reporting person. |
f2 | the options vest over four years, with 25% of the shares subject to the option vesting on june 15, 2017, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. |
f3 | the options vest over four years, with 25% of the shares subject to the option vesting on january 19, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested. |